Literature DB >> 7078608

Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease.

R A Norum, J B Lakier, S Goldstein, A Angel, R B Goldberg, W D Block, D K Noffze, P J Dolphin, J Edelglass, D D Bogorad, P Alaupovic.   

Abstract

We studied two sisters 29 and 31 years old who had skin and tendon xanthomas, corneal clouding, and severe coronary atherosclerosis. Histologic examination showed collections of lipid-laden histiocytes in the skin. The patients' plasma cholesterol concentrations were 177 and 135 mg per deciliter (4.58 and 3.49 mmol per liter). Levels of high-density-lipoprotein cholesterol were 4 and 7 mg per deciliter (0.1 and 0.2 mmol per liter). Only traces of apolipoprotein A-I were detected in whole plasma. The plasma density fraction from 1.06 to 1.21 g per milliliter contained no high-density lipoprotein on high-pressure liquid chromatography, no apolipoprotein A-I on sodium dodecyl sulfate electrophoresis, and only traces of apolipoprotein A-I on radioimmunoassay. Apolipoprotein C-III was also not detectable. The activity of lecithin-cholesterol acyltransferase was 40 per cent of normal. The half-life of infused normal high-density lipoprotein was three days (normal, 5.8 days). The parents and children of these two patients had low levels of high-density-lipoprotein cholesterol and apolipoprotein A-I. These cases support the hypothesis that low concentrations of high-density lipoprotein promote atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7078608     DOI: 10.1056/NEJM198206243062503

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  54 in total

1.  Matters of the heart transcriptome: a brief history of cardiovascular genomics.

Authors:  Pilar M Labordé-Lahoz
Journal:  Tex Heart Inst J       Date:  2002

2.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 3.  Indications for lipid-lowering drugs.

Authors:  J Davignon
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

5.  Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

Authors:  H N Ginsberg; N A Le; I J Goldberg; J C Gibson; A Rubinstein; P Wang-Iverson; R Norum; W V Brown
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

6.  Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4).

Authors:  S K Karathanasis; P Oettgen; I A Haddad; S E Antonarakis
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

7.  Assignment of the apolipoprotein A-I gene to 11q23 based on RFLP in a case with a partial deletion of chromosome 11, del(11)(q23.3----qter).

Authors:  T Arinami; T Hirano; K Kobayashi; Y Yamanouchi; H Hamaguchi
Journal:  Hum Genet       Date:  1990-06       Impact factor: 4.132

8.  Formation of apolipoprotein-specific high-density lipoprotein particles from lipid-free apolipoproteins A-I and A-II.

Authors:  M A Clay; D A Cehic; D H Pyle; K A Rye; P J Barter
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

9.  A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

Authors:  Toni I Pollin; Coleen M Damcott; Haiqing Shen; Sandra H Ott; John Shelton; Richard B Horenstein; Wendy Post; John C McLenithan; Lawrence F Bielak; Patricia A Peyser; Braxton D Mitchell; Michael Miller; Jeffrey R O'Connell; Alan R Shuldiner
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

10.  Apolipoprotein A-I variants. Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I.

Authors:  A von Eckardstein; H Funke; A Henke; K Altland; A Benninghoven; G Assmann
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.